{"log_id": 3657719073246601432, "direction": 0, "words_result_num": 10, "words_result": [{"probability": {"variance": 0.00358, "average": 0.985058, "min": 0.681785}, "location": {"width": 693, "top": 550, "height": 35, "left": 250}, "words": "图2基于研究者评估结果的 Kaplan- Meier曲线计算的至肿瘤进展时间"}, {"probability": {"variance": 0, "average": 0.953494, "min": 0.953494}, "location": {"width": 114, "top": 672, "height": 51, "left": 799}, "words": "有"}, {"probability": {"variance": 0, "average": 0.855418, "min": 0.855418}, "location": {"width": 41, "top": 712, "height": 37, "left": 900}, "words": "7"}, {"probability": {"variance": 0, "average": 0.98806, "min": 0.98806}, "location": {"width": 95, "top": 1083, "height": 26, "left": 910}, "words": " GUANGDONG"}, {"probability": {"variance": 0.000426, "average": 0.992495, "min": 0.907679}, "location": {"width": 746, "top": 1105, "height": 31, "left": 210}, "words": "上述疗效分析时,总生存时间数据尚未成熟(32%事件)。但根P"}, {"probability": {"variance": 0, "average": 0.999555, "min": 0.997949}, "location": {"width": 633, "top": 1134, "height": 35, "left": 207}, "words": "用卡培他滨的患者交叉至拉帕替尼与卡培他滨联用组。研究随"}, {"probability": {"variance": 0.000751, "average": 0.983498, "min": 0.92228}, "location": {"width": 148, "top": 1171, "height": 26, "left": 207}, "words": "数据请见表11"}, {"probability": {"variance": 0.001502, "average": 0.980175, "min": 0.902677}, "location": {"width": 163, "top": 1132, "height": 78, "left": 895}, "words": "药有限公司"}, {"probability": {"variance": 0.039506, "average": 0.75814, "min": 0.424686}, "location": {"width": 83, "top": 1210, "height": 27, "left": 955}, "words": "米11"}, {"probability": {"variance": 0, "average": 0.996341, "min": 0.996155}, "location": {"width": 25, "top": 1530, "height": 22, "left": 644}, "words": "20"}], "language": 3}